CASTLE BIOSCIENCES INC 8-K

What Happened
Castle Biosciences, Inc. (CSTL) filed a Form 8-K on May 6, 2026 announcing its financial results for the quarter ended March 31, 2026. The company attached a press release reporting the Q1 2026 results (Exhibit 99.1) and made an investor slide presentation available (Exhibit 99.2). The 8-K notes these materials were furnished as Regulation FD disclosure.

Key Details

• Date filed: May 6, 2026. Reporting period: quarter ended March 31, 2026.
• Item 2.02: Press release announcing Q1 2026 financial results attached as Exhibit 99.1.
• Item 7.01: Slide presentation made available and attached as Exhibit 99.2 for investor and management use.
• The Form 8-K states the press release and slides are furnished under Reg FD and are not deemed “filed” for Section 18 liability purposes. Document signed by Frank Stokes, CFO.

Why It Matters
This filing signals Castle has publicly released its latest quarterly earnings information and investor materials; those documents are where investors should look for revenue, earnings, guidance, and other quantitative details. Because the materials were furnished under Regulation FD (not formally “filed” under Section 18), investors should review the attached press release and slides directly to assess any impact on revenue, profitability, or near-term outlook.